UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase III Study of Cyclophosphamide, Doxorubicin, and Fluorouracil (CAF) Plus Leucovorin Versus CAF for Metastatic Breast Cancer: Cancer and Leukemia Group B 9140

Journal of clinical oncology, 2003-05, Vol.21 (9), p.1819-1824

2003

Volltextzugriff (PDF)

Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study

Journal of clinical oncology, 1995-03, Vol.13 (3), p.741-747

1995

Volltextzugriff (PDF)

A phase IIa pharmacokinetic and efficacy study of amonafide (AS1413) in combination with cytarabine in patients with acute myeloid leukemia

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS278-TPS278

2010

Volltextzugriff (PDF)

Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors

Journal of clinical oncology, 1994-09, Vol.12 (9), p.1902-1909

1994

Volltextzugriff (PDF)

Treatment-related AML and AML evolving from MDS: Similar outcomes following treatment with amonafide plus cytarabine

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.6582-6582

2010

Volltextzugriff (PDF)

Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621

Journal of clinical oncology, 2004-11, Vol.22 (21), p.4290-4301

2004

Volltextzugriff (PDF)

A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6520-6520

2011

Volltextzugriff (PDF)

Subcutaneous injections of low doses of veltuzumab (humanized anti-CD20 antibody): Objective responses in B-cell malignancies

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.8530-8530

2009

Volltextzugriff (PDF)

Clinical and cytogenetic responses to amonafide in secondary acute myeloid leukemia (AML)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.6584-6584

2006

Volltextzugriff (PDF)

Thalidomide alone or in combination with fludarbabine are effective treatments for patients with fludarabine-relapsed and refractory CLL

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.6640-6640

2005

Volltextzugriff (PDF)

Ig V gene mutation status correlates well with clinical course and outcome regardless of surface membrane isotype expressed by B-CLL cells

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.6562-6562

2004

Volltextzugriff (PDF)

Ig V gene mutation status correlates well with clinical course and outcome regardless of surface membrane isotype expressed by B-CLL cells

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.6562-6562

2004

Volltextzugriff (PDF)

In B-CLL, time to first treatment is dependant on the IgV H gene mutations and expression of CD38 on leukemic cells

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.6555-6555

2005

Volltextzugriff (PDF)

Phase I study of amonafide + cytosine arabinoside (AraC) in patients with poor risk acute myeloid leukemia (AML)

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.6602-6602

2005

Volltextzugriff (PDF)

Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2013-03, Vol.31 (7), p.895-902

2013

Volltextzugriff (PDF)

Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031

Journal of clinical oncology, 2014-11, Vol.32 (32), p.3651-3658

2014

Volltextzugriff (PDF)

Metastatic Lymph Node Burden and Survival in Oral Cavity Cancer

Journal of clinical oncology, 2017-11, Vol.35 (31), p.3601-3609

2017

Volltextzugriff (PDF)

Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study

Journal of clinical oncology, 2015-08, Vol.33 (22), p.2464-2471

2015

Volltextzugriff (PDF)

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

Journal of clinical oncology, 2009-11, Vol.27 (32), p.5410-5417

2009

Volltextzugriff (PDF)

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

Journal of clinical oncology, 2020-09, Vol.38 (26), p.2981-2992

2020

Volltextzugriff (PDF)

Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children's Oncology Group Trial ACNS0333

Journal of clinical oncology, 2020-04, Vol.38 (11), p.1175-1185

2020

Volltextzugriff (PDF)

Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

Journal of clinical oncology, 2008-07, Vol.26 (21), p.3523-3529

2008

Volltextzugriff (PDF)

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

Journal of clinical oncology, 2008-02, Vol.26 (4), p.633-638

2008

Volltextzugriff (PDF)

ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma

Journal of clinical oncology, 2024-05, Vol.42 (13), p.1542-1552

2024

Volltextzugriff (PDF)

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

Journal of clinical oncology, 2017-11, Vol.35 (33), p.3737-3744

2017

Volltextzugriff (PDF)

1 – 25 von 359

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(359)
Mit Volltextzugriff
(349)

Publikationsform

Artikel
(359)

Sprache

Englisch
(359)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(88)
Oncology
(88)
Science & Technology
(88)
Humans
(86)
Female
(69)
Biological And Medical Sciences
(59)
Medical Sciences
(59)
Male
(54)
Adult
(50)
Middle Aged
(41)
Tumors
(37)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(33)
Adolescent
(31)
Aged
(31)
Original Reports
(28)
Child
(27)
Treatment Outcome
(26)
Child, Preschool
(23)
Pharmacology. Drug Treatments
(19)
Antineoplastic Agents
(18)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Phase III Study of Cyclophosphamide, Doxorubicin, and Fluorouracil (CAF) Plus Leucovorin Versus CAF for Metastatic Breast Cancer: Cancer and Leukemia Group B 9140

Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study

A phase IIa pharmacokinetic and efficacy study of amonafide (AS1413) in combination with cytarabine in patients with acute myeloid leukemia

Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors

Treatment-related AML and AML evolving from MDS: Similar outcomes following treatment with amonafide plus cytarabine

Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621

A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE)

Subcutaneous injections of low doses of veltuzumab (humanized anti-CD20 antibody): Objective responses in B-cell malignancies

Clinical and cytogenetic responses to amonafide in secondary acute myeloid leukemia (AML)

Thalidomide alone or in combination with fludarbabine are effective treatments for patients with fludarabine-relapsed and refractory CLL

Ig V gene mutation status correlates well with clinical course and outcome regardless of surface membrane isotype expressed by B-CLL cells

Ig V gene mutation status correlates well with clinical course and outcome regardless of surface membrane isotype expressed by B-CLL cells

In B-CLL, time to first treatment is dependant on the IgV H gene mutations and expression of CD38 on leukemic cells

Phase I study of amonafide + cytosine arabinoside (AraC) in patients with poor risk acute myeloid leukemia (AML)

Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer

Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031

Metastatic Lymph Node Burden and Survival in Oral Cavity Cancer

Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children's Oncology Group Trial ACNS0333

Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

Aktive Filter

Suchergebnisse filtern